GU Oncology Now

🔍 #ICYMI: Check out this research investigating factors that could alter the likelihood of identifying a clinically actionable #germline #pathogenic variant in patients with #UC. 🧠 Learn More:

👀 Check out the latest on the potential of #CEUS characteristics in helping identify distinguishing features of #nccRCC. 🧠 Learn More:

🩺 Don't miss this recent study investigating the connection between neighborhood disadvantage and aggressive #ProstateCancer. 👉 Find the results here:

💵 #ICYMI: Check out this study from Laura Bukavina, MD, MPH, MSc, and colleagues investigating #financial distress among patients with #GU cancers. 🗞️ Read More:

⭐ We're excited to partner with AUC3 to bring their inaugural conference to Miami, Florida in January 2025! The 2-day live event will feature key panel members from diverse medical disciplines to engage in lively discussions and debates on diagnostic and management strategies for kidney and bladder cancer. 👉 Learn More:

🧠 Check out this research investigating the association between #bone pain and survival outcomes in patients with #mHSPC. 📚 Read More:

🔍 A recent study investigated the differences between #nivolumab plus #ipilimumab with #sunitinib for the first-line treatment of advanced #RCC. 🔬 Find the results here:

🎙️ Don't miss part 2 of the conversation between Enrique Grande, MD, PhD, MSc, and Amanda Nizam, MD, on the #EVITA criteria, including the importance of personalizing treatment to predict and manage toxicity. 👀 Watch Here: https://buff.ly/4fBwBXM

💊 Don't miss this real-world study which investigated the correlation between #ARPIs and drug-comorbidity interactions in patients with #mCRPC. 🗞️ Read More:

👀 Are you ready for #UromigosLive 2024? 🎬 Check out this video featuring Brian Rini, MD, FASCO, to find out more!